Less Ads, More Data, More Tools Register for FREE

Pin to quick picksTheracryf PLC Regulatory News (TCF)

Share Price Information for Theracryf PLC (TCF)

Share Price is delayed by 15 minutes
Get Live Data
0.215    0.00 (0.00%)
Bid:
0.19
Ask:
0.24
Spread: 0.05 (26.316%)
Market Cap: £5.05m
TCF Live PriceLast checked at - London Stock Exchange

Intraday Theracryf PLC Share Chart

Holding(s) in Company

16 Oct 2025 16:45

RNS Number : 7274D
Theracryf PLC
16 October 2025
 

 

TR-1: Standard form for notification of major holdings

 

NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) i

1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached ii:

TheraCryf Plc

1b. Please indicate if the issuer is a non-UK issuer (please mark with an "X" if appropriate)

UK

2. Reason for the notification (please mark the appropriate box or boxes with an "X")

An acquisition or disposal of voting rights

x

An acquisition or disposal of financial instruments

An event changing the breakdown of voting rights

Other (please specify) iii:

3. Details of person subject to the notification obligation iv

Name

Northern Standard Limited

City and country of registered office (if applicable)

2nd Floor, Connaught House, St. Julian's Avenue, St. Peter Port, Guernsey, GY1 1RD

4. Full name of shareholder(s) (if different from 3.) v

Name

Fiske Nominees Limited

City and country of registered office (if applicable)

100 Wood Street, London, England, EC2V 7AN

5. Date on which the threshold was crossed or reached vi:

14/10/2025

6. Date on which issuer notified (DD/MM/YYYY):

15/10/2025

7. Total positions of person(s) subject to the notification obligation

% of voting rights attached to shares (total of 8. A)

% of voting rights through financial instruments(total of 8.B 1 + 8.B 2)

Total of both in % (8.A + 8.B)

Total number of voting rights held in issuer (8.A + 8.B) vii

Resulting situation on the date on which threshold was crossed or reached

20.01%

-

20.01%

430,069,568

Position of previous notification (if

applicable)

19.85%

-

19.85%

 

8. Notified details of the resulting situation on the date on which the threshold was crossed or reached viii

A: Voting rights attached to shares

Class/type ofshares

ISIN code (if possible)

Number of voting rights ix

% of voting rights

Direct

(DTR5.1)

Indirect

 (DTR5.2.1)

Direct

(DTR5.1)

Indirect

(DTR5.2.1)

GB00BSVYN304

  430,069,568

-

20.01%

-

SUBTOTAL 8. A

430,069,568

20.01%

 

 

B 1: Financial Instruments according to DTR5.3.1R (1) (a)

Type of financial instrument

Expirationdate x

Exercise/Conversion Period xi

Number of voting rights that may be acquired if the instrument is

exercised/converted.

% of voting rights

SUBTOTAL 8. B 1

B 2: Financial Instruments with similar economic effect according to DTR5.3.1R (1) (b)

Type of financial instrument

Expirationdate x

Exercise/Conversion Period xi

Physical or cash

Settlement xii

Number of voting rights

% of voting rights

 

SUBTOTAL 8.B.2

 

 

 

9. Information in relation to the person subject to the notification obligation (please mark the

applicable box with an "X")

Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer xiii

Full chain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held starting with the ultimate controlling natural person or legal entity (please add additional rows as necessary) xiv

X

Name xv

% of voting rights if it equals or is higher than the notifiable threshold

% of voting rights through financial instruments if it equals or is higher than the notifiable threshold

Total of both if it equals or is higher than the notifiable threshold

Dr John Wardle

-

-

-

Tracarta Limited

-

-

-

Northern Standard Limited

20.01%

-

20.01%

 

10. In case of proxy voting, please identify:

Name of the proxy holder

The number and % of voting rights held

The date until which the voting rights will be held

11. Additional information xvi

Mr. Edward James Norman Wardle, who is a non-executive director of Theracryf, PLC holds a 49% ownership interest in Northern Standard Limited but does not exercise majority control. The chain of control is through Dr John Wardle, who owns 100% of Tracarta Limited, which holds 51% of Northern Standard Limited.

 

 

Place of completion

St. Peter Port, Guernsey

Date of completion

15/10/2025

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
HOLFLFVEIFLRLIE
12
Date   Source Headline
26th May 20262:40 pmRNSHolding(s) in Company
15th May 202612:43 pmRNSHolding(s) in Company
15th May 20267:00 amRNSHolding(s) in Company
14th May 20267:00 amRNSPositive Ox-1 tox data in addiction programme
21st Apr 20267:00 amRNS-RInvestor Webinar
20th Apr 20267:00 amRNSSuccessful GMP Manufacture Advances Ox-1 to Clinic
16th Apr 20267:00 amRNSNew Manufacturing Process Patent for Ox-1
14th Apr 20267:00 amRNSNon-Binding Proposal to Acquire TheraCryf’s Assets
23rd Mar 20267:00 amRNSOx-1 Programme Advances to Final Toxicology Study
26th Jan 20267:00 amRNSOx-1 Addiction Programme Update
5th Jan 20267:00 amRNSKey Ox-1 milestone & notice of investor webinar
18th Dec 20257:00 amRNS-RPotential of Preclinical Program in Mental Fatigue
3rd Dec 20257:00 amRNSHalf-year Financial Report
26th Nov 20257:00 amRNS-RMarking Addiction Awareness Week
24th Nov 20257:00 amRNSNotice of Results
3rd Nov 20257:00 amRNSOx-1 Programme Achieves Manufacturing Milestone
16th Oct 20254:45 pmRNSHolding(s) in Company
16th Oct 20254:45 pmRNSDirector/PDMR Shareholding
10th Oct 20257:00 amRNS-RWorld Mental Health Day & Q4 Conference Schedule
26th Sep 20253:45 pmRNSHolding(s) in Company
8th Sep 202511:38 amRNSHolding(s) in Company
4th Sep 20257:00 amRNSOx-1 Patent Grant & Development Programme Update
4th Aug 20253:27 pmRNSHolding(s) in Company
17th Jul 20257:00 amRNSManufacturing Scale Up of Lead Ox-1 Programme
9th Jul 20253:07 pmRNSResult of AGM
9th Jul 20257:00 amRNSAGM Statement
16th Jun 20254:10 pmRNSNotice of AGM
13th Jun 20257:00 amRNSChange of Adviser
10th Jun 202512:32 pmRNS-ROx-1 Investor Presentation
3rd Jun 20257:00 amRNSFinal results for year to 31 March 2025
23rd May 20257:14 amRNSNotice of Results and Ox-1 presentation
22nd May 202512:43 pmRNSHolding(s) in Company
22nd May 202512:22 pmRNSDirector/PDMR Shareholding
16th May 20251:00 pmRNSHolding(s) in Company
12th May 20257:00 amRNSMaster Service Agreement signed for Ox-1 programme
1st May 20257:00 amRNSBoard Appointment, Grant of Options, PDMR Dealing
26th Mar 20257:00 amRNS-RInvestor webinar
21st Mar 20253:55 pmRNSHolding(s) in Company
20th Mar 20253:33 pmRNSHolding(s) in Company
20th Mar 202511:01 amRNSHolding(s) in Company
19th Mar 202512:10 pmRNSHolding(s) in Company
17th Mar 20252:17 pmRNSHolding(s) in Company
17th Mar 20257:00 amRNSHolding(s) in Company
17th Mar 20257:00 amRNSHolding(s) in Company
17th Mar 20257:00 amRNSHolding(s) in Company
13th Mar 20257:00 amRNSHolding(s) in Company
12th Mar 20252:03 pmRNSHolding(s) in Company
12th Mar 20251:59 pmRNSHolding(s) in Company
11th Mar 202510:17 amRNSHolding(s) in Company
7th Mar 202512:04 pmRNSResult of General Meeting
12

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.